This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Diving into the label expansion for Merck's Prevymis (letermovir) for prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients

Ticker(s): MRK

Who's the expert?

Institution: Northwestern Medicine

  • Medical Director of the Translational Medicine Program & Professor of Medicine (Nephrology and Hypertension) and Surgery (Organ Transplantation) at Northwestern Medicine.
  • Sees 500 kidney transplant patients per year.
  • Research interests include the role of immunosuppressive medications in modulating the immune system, Genomic of chronic renal allograft rejection, Chronic kidney disease after liver transplant, and new immunosuppressive strategies.

Interview Goal
On this call we will be digging into the FDA's approval of Prevymis (letermovir) supported by the phase 3 clinical trial (MK-8228-002) evaluating the safety and efficacy of safety of letermovir to prevent CMV disease in adult kidney transplant recipients at high risk.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.